GlassScriptPhysician profile
Ruth W Thuo
NPI 1871004762
$1,015.98
in general payments reported to CMS, 2019-2025
21 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $90.46 · 2023: $297 · 2024: $54.22 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153.36 | 2021-2025 | Lokelma, Airsupra |
| Vifor Pharma, INC. | $101.46 | 2021 | |
| Cipher Pharmaceuticals US LLC | $99.12 | 2025 | Natroba, Spinosad |
| Fresenius USA Marketing, INC. | $91.13 | 2021-2023 | Velphoro |
| Mylan Specialty L.P. | $90.46 | 2022 | |
| Horizon Therapeutics Plc | $68.74 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $58.07 | 2021-2023 | Acthar |
| Lilly USA, LLC | $55.12 | 2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $50.78 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $36.72 | 2023-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2025 | Jardiance |
| Exact Sciences Corporation | $22.08 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $20.94 | 2023 | Parsabiv, Tavneos |
| Daiichi Sankyo INC. | $20.09 | 2021 | |
| Akebia Therapeutics INC | $18.65 | 2023 | Auryxia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.98 | 2021 | |
| Astellas Pharma US INC | $17.11 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $17.04 | 2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $16.12 | 2025 | Shingrix |
| Opko Pharmaceuticals, LLC | $14.75 | 2021 | |
| Genzyme Corporation | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Thuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.